Podcast Episodes
Back to Search
Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about th…
4 months, 3 weeks ago
Episode 507: ASCO 2026 - TALAPRO-3
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer…
4 months, 3 weeks ago
Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer c…
4 months, 3 weeks ago
Episode 505 : ASCO 2026 - RAMPART
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data …
4 months, 3 weeks ago
Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV30…
4 months, 3 weeks ago
Episode 499: APCCC 2026 - Radioligands in Prostate Cancer
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prost…
5 months ago
Episode 503: ASCO 2026 Preview
Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
5 months ago
Episode 502: AUA 2026 and FDA bladder cancer meeting
In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuan…
5 months ago
Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer
Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
5 months, 1 week ago
Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)
Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers,…
5 months, 2 weeks ago